The new pleuromutilin derivative 81.723 hfu is extremely active against gram-positive organisms such as streptococci, staphylococci, and against mycoplasmas. A number of Shigella, Klebsiella, and Escherichia coli strains were also found to be quite susceptible to this new agent, whereas other gram-negative organisms like Pseudomonas aeruginosa, Proteus species, and Alcaligenes faecalis proved to be naturally resistant to 81.723 hfu. The new compound acts bacteriostatically. Bactericidal effects have been observed only at concentrations which are 100-fold higher than the minimal inhibitory concentrations. The new antibiotic is well tolerated in all animal species tested so far and has been successfully used in the treatment of experimental infections with gram-positive organisms and with mycoplasmas in mice and rats. Resistance against this new compound arose gradually in all microorganisms investigated. It is noteworthy 'that the rate at which resistance against 81.723 hfu emerged in mycoplasmas (Mycoplasma gallisepticum and Mycoplasma hyorhinis) was significantly slower than the corresponding rate at which resistance against tylosin tartrate appeared. Mycoplasma strains which became insensitive to 81.723 hfu were also resistant to tylosin tartrate, whereas mycoplasmas which developed resistance against tylosin tartrate, although less sensitive to 81.723 hfu than wild-type strains, were still eliminated by this drug. In a strain of Klebsiella pneumoniae, complete cross-resistance was observed between the pleuromutilin derivative on one hand and lincomycin and erythromycin on the other. Modest degrees of cross-resistance were also observed with chloramphenicol. However, it appears unlikely that the latter phenomenon is sufficiently pronounced to affect treatment with either antibiotic.
Cultures of the basidomycete Pleurotus mutilis contain a substance with a modest degree of in vitro activity against gram-positive bacteria which was called pleuromutilin (6) . This compound was shown to be a diterpene antibiotic and to have the structure depicted in Fig. 1 (1, 9) . Experiments which will be reported elsewhere demonstrated that the antibacterial activity of pleuromutilin can be greatly enhanced if the glycolic side chain in position 14 of the molecule is replaced by other acyl residues. Following this general strategy, a large number of pleuromutilin derivatives, all of which exhibited considerable antimicrobial activity in vitro and in vivo, were synthesized. From this series, 14 -deoxy-14-[(2-diethylaminoethyl)-mercapto-acetoxy]-mutilin was selected for further study on the basis of the following criteria: (i) availability as a crystalline water-soluble salt (hydrogen fumarate); (ii) outstanding activity against gram-positive bacteria and mycoplasma strains in vitro; (iii) good efficacy against experimental animal infections due to gram-positive bacteria and mycoplasmas; and (iv) low to moderate acute toxicity in several animal species.
The purpose of this paper is to describe the new compound's antimicrobial and chemotherapeutic potential.
MATERIALS AND METHODS Antibiotics. Compound 81.723 hfu was synthesized by procedures which will be described elsewhere (manuscript in preparation). Erythromycin was a gift of Schering AG, Berlin. Lincomycin and spectinomycin came from the Upjohn Co., Kalamazoo, Mich. Tetracycline-hydrochloride was obtained commercially.
Organisms. If not otherwise stated, bacteria were isolated from the Tierarztliche Hochschule, Vienna, or from this institute. The isolated organisms were classified according to the taxonomic criteria laid down in Bergey's Manual of Determinative Bacteriol-ANTIMICROB. AGENTS CHEMOTHER. In vitro activity. MICs for bacteria and mycoplasmas were determined by serial twofold dilution tests in the appropriate media.
Development of resistance in vitro. The development of bacterial resistance against antibiotics was studied by growing the respective organisms in the presence of various concentrations of the drug against which resistance was to be generated. From the tube containing the highest concentration of antibiotic which still allowed normal or nearly normal growth, successive transfers were made every 48 h into the next series of tubes containing the same or higher concentrations of the antibiotic. The same technique was used for the generation of resistance of mycoplasmas.
Bacteriostatic versus bactericidal activity in vitro. Samples (1.2 ml) of Trypticase soy broth containing compound 81.723 hfu in con .entrations increasing geometrically from 0.039 to 10 ;sg/ml were inoculated with 103 organisms of Staphylococcus aureus SG 511 and incubated at 37 C for 18 h. Control tubes contained no antibiotic. Aliquots (0.1 ml) from these cultures were plated on blood agar. After 24 h of incubation the number of colonies on each plate was counted. This experiment was carried out at pH 7.3 and 8.0.
Protein biosynthesis. Klebsiella pneumoniae wild type and mutants resistant against 81.723 hfu were grown in Trypticase soy broth to half-logarithmic phase. The cells were then harvested, and the ribosomes were isolated according to Nirenberg (10) . Twenty absorbancy units of these ribosomes at 260 nm were then introduced into a cell-free, protein-synthesizing system containing (in volumes of 0.25 ml): 500 /ig of a 100,000 x g supernatant from Escherichia coli K-12 as determined by the method of Lowry et al. otic was introduced to give final concentrations between 10-9 and 10-2 M. Incubations which lasted 15 min at 37 C were terminated by precipitation with 10% (wt/vol) ice-cold trichloroacetic acid. After centrifugation, the precipitates were resuspended in 10% trichloroacetic acid and kept at 90 C for 30 min. They were then centrifuged and washed four times with cold trichloroacetic acid. Subsequently, the samples were applied to nitrocellulose filters for scintillation counting. The radioactivity of samples incubated in the absence of the inhibitor were called 100% and the data obtained in the presence of the anitbiotic were plotted as percentage of controls.
Acute toxicity. Acute toxicity experiments were performed in four animal species: female mice, male chickens, 4-week-old male and female pigeons, and 3-week-old male and female turkeys. 81,723 hfu was administered to these animals as a single dose either perorally, subcutaneously, or intramuscularly. There were six dosage groups for each animal species and each route of administration. Each group consisted of at least 10 animals. After administration of the drug, the animals were observed continuously for 5 h and daily for a subsequent period of 2 weeks. The mortality in each group was recorded, and dose response curves were drawn for each experimental group. The mean lethal dose (LD) values for 5, 50, and 95% of the animals were then computed by probit analysis according to Bliss (2) .
Experimental infections of mice. Animals were infected intraperitoneally with 0. Table 5 were obtained by incubating the test strains on 1.4% Trypticase soy agar in the presence of increasing concentrations of the respective antibiotic and by passaging those colonies which had grown on the highest concentration of antibiotic. In our experiments, the increase in resistance against 81.723 hfu occurred gradually and followed the multiple-step pattern. In mycoplasmas, resistance against 81.723 hfu appeared to emerge even more slowly. Figure 2 illustrates Micrococcus Ox- Correspondingly, mutants of the same Klebsiella strain which had been selected for their resistance to lincomycin and erythromycin also proved to be resistant to the pleuromutilin derivative.
A less characteristic pattern of cross-resistance was found to exist in two species of S. aureus. Mutants of S. aureus SG 511 and S. aureus ATCC 10390 which had acquired resistance to 81.723 hfu only showed a modest loss of sensitivity to lincomycin and almost no alteration in their sensitivity to erythromycin. Representatives of these two strains which had developed resistance to lincomycin displayed only a three-to sixfold increase in their resistance to 81.723 hfu. Erythromycin-and spectinomycinresistant mutants of these two strains remained fully susceptible to the pleuromutilin derivative.
In a recent publication from this laboratory, Hodgin and Hogenauer (5) demonstrated an inhibition of bacterial protein synthesis to be the biochemical basis for the antibacterial action of pleuromutilin derivatives. It was shown by these authors that pleuromutilin derivatives prevent the binding of aminoacyl-transfer ribonucleic acid to the ribosomal A site if a peptidyl transfer ribonucleic acid or an initiator transfer ribonucleic acid occupies the ribosomal P site (5). This finding, as well as the occurrence of cross-resistance with erythromycin and lincomycin in mutants of K. pneumoniae described above and to chloramphenicol in other bacterial mutants (14) , raised the possibility that an 512 DREWS ET AL.
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on October 25, 2017 by guest http://aac.asm.org/ Downloaded from alteration of the bacterial ribosome might represent the biochemical basis for resistance to 81.723 hfii. This hypothesis was put to experimental trial by isolating ribosomes from a sensitive wild type of K. pneumoniae and frotn six mutants from this organism which had become resistant agaitist 81.723 hfu. These ribosomes were then introduced into a cl4ssical cell-free system for protein synthesis, in which all other cellular components necessary for the formation of polyphenylalanine coded by polyuridylic acid Were derived from E. coli. It was found that the concentrations of 81.723 hfu necessary to produce a 50% inhibition of protein ITIMICROBIAL ACTIVITIES OF 81.723 HFU 513 synthesis ip those assays which contained ribosomes froi resistant strains was higher by three to fout orders of magnitude than the concentratiorn of the antibiotic which had the satne effect in the control system containing ribosomes from the sensitive wild-type strain (Fig. 3) . It was concluded from these experiments that an alteration of the bacterial ribosome provides at least one mechanism by which bacteria can become resistant to 81.723 hfu.
In vivo experiments with compound 81.723 hfu. A summary of data relating to the acute toxicity of the new antibiotic in four animal species is given in Table 7 . As also observed with macrolides, resistance to 81.723 hfu emerges in bacteria in a step wise fashion, but rather rapidly. In mycoplasmas, however, resistance to 81.723 hfu evolves more slowly than in bacteria. Moreover, the levels of resistance to 81.723 hfu attained by two pathogenic mycoplasmas after 20 in vitro passages appear modest compared to the corresponding resistance to tylosin tartrate expressed in these strains after the same number of passages. The complete cross-resistance between 81.723 hfu and erythromycin or lincomycin which was observed in K. pneumoniae appears to be in line with the fact that all of these antibiotics are inhibitors of the large (50S) subunit of the bacterial rib6some. However, in the two S. aureus strains which were investigated, crossresistance between these antibiotics could not be detected, whereas in M. gallisepticum and M. hyorhinis cross-resistance between tylosin tartrate and 81.723 hfu was only partial. Therefore, it appears possible that the biochemical mechanisms which produce resistance to 81.723 hfu in staphylococci and mycoplasmas are different from each other as well as from the analogous mechanisms operating in K. pneumoniae. Ditta presented in this and in the accompanying paper (7) show that 81.723 hfu is effective in the treatment of model infections with grampositive bacteria and mycoplasxtias-MQreover, as judged by the acute toxicity data in four animal species, the new compound appears to exhibit only low toxicity, especially after oral administration. These findings, as well as the lack of cross-resistance with erythromycin and lincomycin in staphylococci, the slow development of resistance in mycoplasmas, and the fact that mycoplasmas with high levels of resistance to tylosin tartrate appear to lose little of their susceptibility to 81.723 hfu, have made the new attibiotic an interesting candidate for fuirther development. Studies aimed at the complete delineation of this compound's chemotherapeutic potential are now is progress.
